Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MLLT1 | Q03111 | 12/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | MLLT3 | P42568 | 4/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | YEATS2 | Q9ULM3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15008043 | 0.74 | MAPK14 (0.54) | DNMT1SCN5AMAPK14MLLT1MAOB | |
| SCHEMBL2736776 | 0.74 | DNMT1 (0.46) | DNMT1SCN5AMAPK14MLLT1MAOB | |
| SCHEMBL252922 | 0.74 | PIK3CG (0.47) | DNMT1SCN5AMAPK14MLLT1MAOB | |
| SCHEMBL24816112 | 0.74 | DNMT1 (0.46) | DNMT1SCN5AMAPK14MLLT1MAOB | |
| SCHEMBL17425964 | 0.74 | MLLT1 (0.44) | DNMT1SCN5AMAPK14MLLT1MLLT3 | |
| SCHEMBL23432690 | 0.72 | MLLT1 (0.49) | DNMT1SCN5AMAPK14MLLT1MAOB | |
| SCHEMBL23618940 | 0.71 | KDM4E (0.37) | DNMT1SCN5AMLLT1MAOBKDM4E | |
| SCHEMBL2669666 | 0.69 | DNMT1 (0.42) | DNMT1SCN5AMAPK14MLLT1MAOB | |
| SCHEMBL6813380 | 0.69 | MLLT1 (0.58) | DNMT1SCN5AMAPK14MLLT1MLLT3 | |
| SCHEMBL11379662 | 0.69 | SCN5A (0.59) | DNMT1SCN5AMAPK14TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230167068-A1 | BENZOPYRAZOLE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230167068-A1 | BENZOPYRAZOLE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-06-01 | — | — | US | disclosed |
| EP-3686199-B9 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS SUZHOU CO LTD (CN) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021136431-A1 | BENZO[D][1,2,3]TRIAZOLE ETHER COMPOUND | 南京明德新药研发有限公司 | 2021-07-08 | — | — | WO | disclosed |
| WO-2021136429-A1 | BENZOPYRAZOLE COMPOUND | 南京明德新药研发有限公司 | 2021-07-08 | — | — | WO | disclosed |
| EP-3686199-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2020-07-29 | — | — | EP | disclosed |
| EP-2802576-B1 | HETEROCYCLIC-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2018086585-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATIONS THEREOF | 山东罗欣药业集团股份有限公司 | 2018-05-17 | — | — | WO | disclosed |
| WO-2015051341-A1 | INHIBITORS OF ERK AND METHODS OF USE | ARAXES PHARMA LLC (US) | 2015-04-09 | — | — | WO | disclosed |
| EP-2818471-A1 | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-12-31 | — | — | EP | disclosed |
| EP-2818471-A1 | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-12-31 | — | — | EP | disclosed |
| EP-1562925-B1 | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2007-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167068-A1 | BENZOPYRAZOLE COMPOUND | ABCB1, CYP3A43, CYP3A5 | DNMT1 4782/4885SCN5A 464/4885MAPK14 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.